Bioceres SA, a key company in the Rosario group promoted by producers, was declared bankrupt in early March amid significant internal shareholder conflicts. This crisis, however, is largely confined to Bioceres itself since its controlling entity, Moolec Science SA, still boasts a global portfolio with biotechnology assets valued at over $160 million spread across Argentina, the United States, and Europe. This suggests a disconnect between the local company’s financial troubles and the larger group's financial health.

Examining the corporate structure and financial statements through filings with the U.S. Securities and Exchange Commission reveals vital insights into cash flows, installed capacity, and liabilities of Moolec Science SA, which is operated under the guidance of Uruguayan businessman Juan Sartori. Notably, Bioceres SA had accumulated significant debt and a negative net worth, which likely contributed to its downfall, emphasizing the intricate dynamics and potential mismanagement within the group.

The implications of this bankruptcy extend beyond Bioceres, posing potential risks to investors and other stakeholders associated with Moolec Science SA. Observers will closely monitor how the company navigates this turmoil, as its substantial assets could be leveraged to mitigate the fallout from Bioceres’s closure and ascertain its operational future in the competitive biotechnology sector.